Johnson & Johnson (NYSE:JNJ) – Analysts at Jefferies Group increased their FY2018 earnings per share estimates for Johnson & Johnson in a note issued to investors on Wednesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings of $8.18 per share for the year, up from their previous estimate of $7.88. Jefferies Group currently has a “Buy” rating and a $157.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $8.96 EPS, FY2020 earnings at $9.69 EPS and FY2021 earnings at $10.58 EPS.

Several other research firms also recently issued reports on JNJ. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price target on the stock. in a research note on Friday. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. BTIG Research downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target on the stock. in a research note on Friday, July 21st. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target on the stock. in a research note on Friday, July 21st. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $135.98.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/13/jefferies-group-comments-on-johnson-johnsons-fy2018-earnings-jnj.html.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period in the prior year, the firm posted $1.74 EPS. The business’s revenue was up 1.9% compared to the same quarter last year.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Large investors have recently bought and sold shares of the business. Lynch & Associates IN increased its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after buying an additional 841 shares during the last quarter. Oakbrook Investments LLC increased its stake in Johnson & Johnson by 7.4% in the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after buying an additional 9,375 shares during the last quarter. Trexquant Investment LP purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $1,731,000. Bollard Group LLC increased its stake in Johnson & Johnson by 5.0% in the 2nd quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after buying an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. increased its stake in Johnson & Johnson by 278.0% in the 2nd quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after buying an additional 177,900 shares during the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.